Aclacinomycin A and etoposide (VP-16-213): An effective regimen in previously treated patients with refractory acute myelogenous leukemia

J. M. Rowe, Alex Y Chang, J. M. Bennett

Research output: Contribution to journalArticle

Abstract

Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213 (100 mg/m2/day for 5 days). All were previously treated and had relapsed or were refractory to primary treatment. Most patients (28) had received prior DAT (daunorubicin, cytosine arabinoside, and 6-thioguanine) induction therapy followed by one or more courses of high-dose cytosine arabinoside (HD-Ara C) as consolidation therapy or as treatment for relapse. One patient was in her fourth relapse, one had relapsed acute megakaryoblastic leukemia (following remission with DAT and HD-Ara-C), one had a treatment-induced leukemia, and four patients were treated for primary treatment failures following two induction courses with DAT or a similar regimen. Fourteen patients had infections at start of therapy. Ten patients died within 14 days of treatment, all from sepsis or bleeding, before their marrow could be evaluated for leukemic response. Fourteen patients (40%) responded; 12 (34%) entered complete remission and two (6%) a partial remission (PR). Two of the four patients who were treated for primary treatment failures went into CR. The median CR duration was 99 days (range 30 to 455 days). Side effects from this treatment were similar to the conventional DAT regimen, although the gastrointestinal toxicity and mucositis appeared to be more severe. In addition, two of the patients had severe but reversible ventricular arrhythmias. The overall response (40%) and CR rate (34%) in this group of previously treated AML patients is encouraging, and further studies are needed to evaluate these preliminary findings.

Original languageEnglish (US)
Pages (from-to)992-996
Number of pages5
JournalBlood
Volume71
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Aclarubicin
Cytarabine
Etoposide
Acute Myeloid Leukemia
Refractory materials
Thioguanine
Daunorubicin
Consolidation
Toxicity
Therapeutics
Treatment Failure
Leukemia, Megakaryoblastic, Acute
Recurrence
Mucositis
Cardiac Arrhythmias
Sepsis
Leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Aclacinomycin A and etoposide (VP-16-213) : An effective regimen in previously treated patients with refractory acute myelogenous leukemia. / Rowe, J. M.; Chang, Alex Y; Bennett, J. M.

In: Blood, Vol. 71, No. 4, 1988, p. 992-996.

Research output: Contribution to journalArticle

@article{6ab97a558c224f6bb7cae67ba4f31d09,
title = "Aclacinomycin A and etoposide (VP-16-213): An effective regimen in previously treated patients with refractory acute myelogenous leukemia",
abstract = "Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213 (100 mg/m2/day for 5 days). All were previously treated and had relapsed or were refractory to primary treatment. Most patients (28) had received prior DAT (daunorubicin, cytosine arabinoside, and 6-thioguanine) induction therapy followed by one or more courses of high-dose cytosine arabinoside (HD-Ara C) as consolidation therapy or as treatment for relapse. One patient was in her fourth relapse, one had relapsed acute megakaryoblastic leukemia (following remission with DAT and HD-Ara-C), one had a treatment-induced leukemia, and four patients were treated for primary treatment failures following two induction courses with DAT or a similar regimen. Fourteen patients had infections at start of therapy. Ten patients died within 14 days of treatment, all from sepsis or bleeding, before their marrow could be evaluated for leukemic response. Fourteen patients (40{\%}) responded; 12 (34{\%}) entered complete remission and two (6{\%}) a partial remission (PR). Two of the four patients who were treated for primary treatment failures went into CR. The median CR duration was 99 days (range 30 to 455 days). Side effects from this treatment were similar to the conventional DAT regimen, although the gastrointestinal toxicity and mucositis appeared to be more severe. In addition, two of the patients had severe but reversible ventricular arrhythmias. The overall response (40{\%}) and CR rate (34{\%}) in this group of previously treated AML patients is encouraging, and further studies are needed to evaluate these preliminary findings.",
author = "Rowe, {J. M.} and Chang, {Alex Y} and Bennett, {J. M.}",
year = "1988",
language = "English (US)",
volume = "71",
pages = "992--996",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Aclacinomycin A and etoposide (VP-16-213)

T2 - An effective regimen in previously treated patients with refractory acute myelogenous leukemia

AU - Rowe, J. M.

AU - Chang, Alex Y

AU - Bennett, J. M.

PY - 1988

Y1 - 1988

N2 - Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213 (100 mg/m2/day for 5 days). All were previously treated and had relapsed or were refractory to primary treatment. Most patients (28) had received prior DAT (daunorubicin, cytosine arabinoside, and 6-thioguanine) induction therapy followed by one or more courses of high-dose cytosine arabinoside (HD-Ara C) as consolidation therapy or as treatment for relapse. One patient was in her fourth relapse, one had relapsed acute megakaryoblastic leukemia (following remission with DAT and HD-Ara-C), one had a treatment-induced leukemia, and four patients were treated for primary treatment failures following two induction courses with DAT or a similar regimen. Fourteen patients had infections at start of therapy. Ten patients died within 14 days of treatment, all from sepsis or bleeding, before their marrow could be evaluated for leukemic response. Fourteen patients (40%) responded; 12 (34%) entered complete remission and two (6%) a partial remission (PR). Two of the four patients who were treated for primary treatment failures went into CR. The median CR duration was 99 days (range 30 to 455 days). Side effects from this treatment were similar to the conventional DAT regimen, although the gastrointestinal toxicity and mucositis appeared to be more severe. In addition, two of the patients had severe but reversible ventricular arrhythmias. The overall response (40%) and CR rate (34%) in this group of previously treated AML patients is encouraging, and further studies are needed to evaluate these preliminary findings.

AB - Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213 (100 mg/m2/day for 5 days). All were previously treated and had relapsed or were refractory to primary treatment. Most patients (28) had received prior DAT (daunorubicin, cytosine arabinoside, and 6-thioguanine) induction therapy followed by one or more courses of high-dose cytosine arabinoside (HD-Ara C) as consolidation therapy or as treatment for relapse. One patient was in her fourth relapse, one had relapsed acute megakaryoblastic leukemia (following remission with DAT and HD-Ara-C), one had a treatment-induced leukemia, and four patients were treated for primary treatment failures following two induction courses with DAT or a similar regimen. Fourteen patients had infections at start of therapy. Ten patients died within 14 days of treatment, all from sepsis or bleeding, before their marrow could be evaluated for leukemic response. Fourteen patients (40%) responded; 12 (34%) entered complete remission and two (6%) a partial remission (PR). Two of the four patients who were treated for primary treatment failures went into CR. The median CR duration was 99 days (range 30 to 455 days). Side effects from this treatment were similar to the conventional DAT regimen, although the gastrointestinal toxicity and mucositis appeared to be more severe. In addition, two of the patients had severe but reversible ventricular arrhythmias. The overall response (40%) and CR rate (34%) in this group of previously treated AML patients is encouraging, and further studies are needed to evaluate these preliminary findings.

UR - http://www.scopus.com/inward/record.url?scp=0023951370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023951370&partnerID=8YFLogxK

M3 - Article

C2 - 3162695

AN - SCOPUS:0023951370

VL - 71

SP - 992

EP - 996

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -